Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
8.88
USD
|
-3.06%
|
|
-6.33%
|
+174.92%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,225
|
1,043
|
901.4
|
304.9
|
1,060
|
-
|
-
|
Enterprise Value (EV)
1 |
941.1
|
728.4
|
689.6
|
234.8
|
697
|
663
|
555.5
|
P/E ratio
|
-7.4
x
|
-4.96
x
|
-2.61
x
|
-0.85
x
|
-5.42
x
|
-7.82
x
|
-139
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
245
x
|
5.11
x
|
6.45
x
|
4.34
x
|
2.66
x
|
EV / Revenue
|
-
|
-
|
187
x
|
3.94
x
|
4.24
x
|
2.71
x
|
1.4
x
|
EV / EBITDA
|
-6.89
x
|
-3.53
x
|
-2.29
x
|
-0.98
x
|
-4.02
x
|
-4.86
x
|
-11
x
|
EV / FCF
|
-8.3
x
|
-4.15
x
|
-2.67
x
|
-0.95
x
|
-5.45
x
|
-9.21
x
|
6.46
x
|
FCF Yield
|
-12%
|
-24.1%
|
-37.4%
|
-105%
|
-18.4%
|
-10.9%
|
15.5%
|
Price to Book
|
-
|
3.5
x
|
4.31
x
|
2.52
x
|
6.64
x
|
5.8
x
|
3.97
x
|
Nbr of stocks (in thousands)
|
43,566
|
50,295
|
60,909
|
94,382
|
115,764
|
-
|
-
|
Reference price
2 |
28.13
|
20.74
|
14.80
|
3.230
|
9.160
|
9.160
|
9.160
|
Announcement Date
|
2/16/21
|
2/22/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
3.686
|
59.61
|
164.4
|
244.3
|
398
|
EBITDA
1 |
-43.06
|
-136.5
|
-206.1
|
-301
|
-240.3
|
-173.2
|
-136.4
|
-50.44
|
EBIT
1 |
-43.13
|
-136.6
|
-206.5
|
-301.6
|
-241.1
|
-173.3
|
-128.3
|
-11.26
|
Operating Margin
|
-
|
-
|
-
|
-8,183.04%
|
-404.49%
|
-105.43%
|
-52.51%
|
-2.83%
|
Earnings before Tax (EBT)
1 |
-
|
-135.7
|
-206.4
|
-311.5
|
-259
|
-188.5
|
-142.1
|
-11.06
|
Net income
1 |
-
|
-135.7
|
-206.4
|
-311.5
|
-262.1
|
-188.5
|
-142.1
|
-11.06
|
Net margin
|
-
|
-
|
-
|
-8,449.76%
|
-439.79%
|
-114.65%
|
-58.18%
|
-2.78%
|
EPS
2 |
-
|
-3.800
|
-4.180
|
-5.660
|
-3.780
|
-1.690
|
-1.172
|
-0.0660
|
Free Cash Flow
1 |
-43.13
|
-113.3
|
-175.6
|
-258
|
-247.5
|
-128
|
-72
|
86
|
FCF margin
|
-
|
-
|
-
|
-7,000.76%
|
-415.2%
|
-77.85%
|
-29.48%
|
21.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
2/16/21
|
2/22/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
0.725
|
2.961
|
2.781
|
5.19
|
38.11
|
13.53
|
49.57
|
27.68
|
35.72
|
47.08
|
55
|
63
|
EBITDA
|
-71.15
|
-62.48
|
-
|
-104.6
|
-68.26
|
-76.09
|
-66.56
|
-36.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-71.29
|
-62.63
|
-65.83
|
-104.7
|
-68.42
|
-76.26
|
-66.76
|
-36.9
|
-61.17
|
-31.62
|
-53.84
|
-48.19
|
-41.18
|
-35.4
|
-31.6
|
Operating Margin
|
-
|
-
|
-
|
-14,448%
|
-2,310.84%
|
-2,742.36%
|
-1,286.38%
|
-96.84%
|
-452.23%
|
-63.79%
|
-194.53%
|
-134.9%
|
-87.48%
|
-64.36%
|
-50.16%
|
Earnings before Tax (EBT)
1 |
-71.33
|
-64.32
|
-67.41
|
-107.7
|
-72.02
|
-80.1
|
-70.99
|
-41.74
|
-66.26
|
-35.06
|
-58.03
|
-52.07
|
-45.83
|
-35.4
|
-31.6
|
Net income
1 |
-71.33
|
-64.32
|
-67.41
|
-107.7
|
-72.02
|
-80.1
|
-70.99
|
-44.76
|
-66.28
|
-35.38
|
-58.03
|
-52.07
|
-45.73
|
-35.4
|
-31.6
|
Net margin
|
-
|
-
|
-
|
-14,856.41%
|
-2,432.25%
|
-2,880.26%
|
-1,367.84%
|
-117.47%
|
-490.05%
|
-71.38%
|
-209.7%
|
-145.74%
|
-97.14%
|
-64.36%
|
-50.16%
|
EPS
2 |
-1.420
|
-1.270
|
-1.310
|
-1.890
|
-1.180
|
-1.310
|
-1.160
|
-0.7300
|
-0.7200
|
-0.3200
|
-0.5300
|
-0.4600
|
-0.4100
|
-0.3000
|
-0.3000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/22/22
|
5/5/22
|
8/4/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/3/23
|
2/27/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
63.3
|
284
|
315
|
212
|
70.1
|
363
|
397
|
505
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-43.1
|
-113
|
-176
|
-258
|
-247
|
-128
|
-72
|
86
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-72.6%
|
-123%
|
-176%
|
-152%
|
-79.7%
|
-27%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
5.920
|
3.430
|
1.280
|
1.380
|
1.580
|
2.310
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.32
|
1
|
0.33
|
0.43
|
3
|
4
|
5
|
Capex / Sales
|
-
|
-
|
-
|
9.03%
|
0.72%
|
1.82%
|
1.64%
|
1.26%
|
Announcement Date
|
3/19/20
|
2/16/21
|
2/22/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
8.88
USD Average target price
19
USD Spread / Average Target +113.96% Consensus |
1st Jan change
|
Capi.
|
---|
| +174.92% | 1.06B | | +9.83% | 118B | | +10.80% | 106B | | -10.84% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.11% | 15.97B | | +6.62% | 14.03B | | +17.53% | 11.67B |
Bio Therapeutic Drugs
|